Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization

Blood

Volumn 111, Issue 6, 2008, Pages 3266-3275

  Xu, Hong ^a   Yan, Jun ^a   Huang, Yiming ^a   Chilton, Paula M ^a   Ding, Chuanlin ^a   Schanie, Carrie L ^a   Wang, Li ^a   Ildstad, Suzanne T ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; CD40 ANTIGEN; CD40 LIGAND; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN RECEPTOR;

ALLOGRAFT; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE ACTIVATION; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT SURVIVAL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION; SKIN GRAFT; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; ANIMAL; B LYMPHOCYTE; BIOSYNTHESIS; BONE MARROW; GENETICS; GERMINAL CENTER; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; METABOLISM; MOUSE MUTANT; SIGNAL TRANSDUCTION; SKIN TRANSPLANTATION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD40; B-LYMPHOCYTES; BONE MARROW; CD40 LIGAND; GERMINAL CENTER; GRAFT SURVIVAL; INTERFERON TYPE II; INTERLEUKIN-10; ISOANTIGENS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SIGNAL TRANSDUCTION; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 42449097699     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2006-10-053801     Document Type: Article

References (51)

1. Blondeau B. The sensitized patient. The Immunology Report. 2005;2:17-20.
2. Baid S, Saidman SL, Tolkoff-Rubin N, et al. Managing the highly sensitized transplant recipient and B cell tolerance. Curr Opin Immunol. 2001; 13:577-581.
3. Fowler DH. B-ware of allosensitized graft rejection. Blood. 2007;109:851-852.
4. Kumpati GS, Cook DJ, Blackstone EH. et al. HLA sensitization in ventricular assist device recipients: does type of device make a difference? J Thorac Cardiovasc Surg. 2004;127:1800-1807.
5. Joyce DL, Southard RE, Torre-Amione G, et al. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on posttransplant outcomes. J Heart Lung Transplant. 2005;24:2054-2059.
6. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735-739.
7. Higuchi ML, Bocchi E, Fiorelli A, et al. [Histopathologic aspects of hyperacute graft rejection in human cardiac transplantation. A case report]. Ar Qbras Cardiol. 1989;52:39-41.
8. Colson YL Schuchert MJ, Ildstad ST. The abrogation of allosensitization following the induction of mixed allogeneic chimerism. J Immunol. 2000; 165:637-644.
9. Shaddy RE, Fuller TC, Anderson JB, et al. Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation. Ann Thorac Surg. 2004;77:1734-1739.
10. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant. 1999;18:701-706.
11. Bartholomew A, Sher D, Sosler S, et al. Stem cell transplantation eliminates alloantibody in a highly sensitized patient. Transplantation. 2001;72: 1653-1655.
12. Xu H, Chilton PM, Tanner MK, et al. Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients. Blood. 2006;108:3611-3619.
13. Gottlieb M, Strober S. Kaplan HS. Allogeneic marrow transplantation after total lymphoid irradiation (TLI): effect of dose/fraction, thymic irradiation, delayed marrow infusion, and presensitization. J Immunol. 1979;123:379-383.
14. Tutschka PJ, Santos GW. Bone marrow transplantation in the busulfan-treated rat, II: effect of cyclophosphamide and antithymic serum on the presensitized state. Transplantation. 1975;20: 116-122.
15. Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Noelle RJ. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+T cells. J Immunol. 1993;151:2497-2510.
16. Van KC, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9:330-337.
17. Bishop GA, Hostager BS. Molecular mechanisms of CD40 signaling. Arch Immunol Ther Exp. (Warsz.) 2001;49:129-137.
18. Xu H, Chilton PM, Huang Y, Schanie CL, lldstad ST. Production of donor T cells is critical for induction of donor-specific tolerance and maintenance of chimerism. J Immunol. 2004;172:1463-1471.
19. Billingham RE. Free skin grafting in mammals. Philadephia, PA: The Wistar Institute Press; 1961.
20. Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol. 2002;169:4667-4673.
21. Williams MA, Trambley J, Ha J, et al. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. J Immunol. 2000;165:6849-6857.
22. Harada H, Salama AD, Sho M, et al. The role of the ICOS-B7h Tcell costimulatory pathway in transplantation immunity. J Clin Invest. 2003;112: 234-243.
23. Iwakoshi NN, Mordes JP, MarkeesTG, etal. Treatment of allograft recipients with donorspecific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol. 2000;164:512-521.
24. Markees TG, Phillips NE, Noelle RJ, et al. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Transplantation. 1997;64:329-335.
25. Tinckam KJ, Sayegh MH. Transplantation tolerance in pediatric recipients: lessons and challenges. Pediatr Transplant. 2005;9:17-27.
26. Keown PA. The highly sensitized patient: etiology, impact and management. Transplant Proc. 1987; 19:74-78.
27. Friedman DF, Lukas MB, Jawad A, et al. Alloimmunization to platelets in heavily transfused patients with sickle cell disease. Blood. 1996;88: 3216-3222.
28. Warren RP, Storb R, Weiden PL, Mickelson EM, Thomas ED. Direct and antibody-dependent cellmediated cytotoxicity against HLA identical sibling lymphocytes: correlation with marrow graft rejection. Transplantation. 1976;22:631-635.
29. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197-204.
30. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-548.
31. Watts TH. Tnf/Tnfr family members in costimulation of Tcell responses. Annu Rev Immunol. 2005;23:23-68.
32. Noel PJ, Boise LH, Thompson CB. Regulation of Tcell activation by CD28 and CTLA4. Adv Exp Med Biol. 1996;406:209-217.
33. Rothstein DM, Livak MF, Kishimoto K, et al. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol. 2001;166:322-329.
34. WekerleT Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med. 2000; 6:464-469.
35. Markees TG, Serreze DV, Phillips NE, et al. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes. 1999;48:967-974.
36. Durham MM, Bingaman AW, Adams AB, et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreduotive conditioning. J Immunol. 2000;165: 1-4.
37. Rosenberg AS, MunitzTI, ManieroTG, Singer A. Cellular basis of skin allograft rejection across a class I major histocompatibility barrier in mice depleted of CD8+ Tcells in vivo. J Exp Med. 1991;173:1463-1471.
38. Ito H, Takeuchi Y, Shaffer J, Sykes M. Local irradiation enhances congenic donor pluripotent hematopoietic stem cell engraftment similarly in irradiated and nonirradiated sites. Blood. 2004;103: 1949-1954.
39. KawabeT, NakaT, Yoshida K, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity. 1994;1:167-178.
40. Gray D, Dullforce P, Jainandunsing S. Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction. J Exp Med. 1994;180: 141-155.
41. Hummelshoj L, Ryder LP, Poulsen LK. The role of the interleukin-10 subfamily members in immunoglobulin production by human B cells. Scand J Immunol. 2006;64:40-47.
42. Balabanian K, Foussat A. Bouchet-Delbos L, et al. Interleukin-10 modulates the sensitivity of peritoneal B lymphocytes to chemokines with opposite effects on stromal cell-derived factor-1 and B-lymphocyte chemoattractant. Blood. 2002;99: 427-436.
43. Taylor PA, Ehrhardt MJ, Roforth MM, et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood. 2007;109:1307-1315.
44. Nagata S, Okano S, Yonemitsu Y, et al. Critical roles of memory Tcells and antidonor immunoglobulin in rejection of allogeneic bone marrow cells in sensitized recipient mice. Transplantation. 2006;82:689-698.
45. Zhang Q, Chen Y, Fairchild RL, Heeger PS. Valujskikh A. Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival. J Immunol. 2006;176:770-777.
46. Ito T, Ueno T, Clarkson MR, et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CDS T cell-mediated alloimmune responses in vivo. J Immunol. 2005;174:6648-6656.
47. Zheng XX, Markees TG, Hancock WW, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol. 1999;162:4983-4990.
48. Hancock WW, Buelow R, Sayegh MH, Turka LA. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med. 1998;4:1392-1396.
49. Hancock WW, Sayegh MH, Zheng XG, et al. Costimulatory function and expression of CD40 ligand, CD80 and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci U S A. 1996;93:13967-13972.
50. Weiden PL, Storb R, Slichter S, Warren RP, Sale GE. Effect of six weekly transfusions on canine marrow grafts: tests for sensitization and abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol. 1976;117:143-150.
51. Krishnamurti L, Blazar BR, Wagner JE. Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med. 2001;344:68.